{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:03:24Z","timestamp":1791450204861,"version":"4.3.3"},"reference-count":56,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"9","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>With an increase in approved targeted therapies for non\u2013small cell lung cancer (NSCLC), tumor profiling that maximizes identification of patients eligible for these treatments is essential. In this study, we compare testing approaches for newly diagnosed advanced or metastatic NSCLC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>An economic model was developed to estimate the annual costs and clinical outcomes associated with testing alternatives. Patients were assigned alterations on the basis of rates observed in published literature. Treatment approaches included no genomic testing; sequential single-gene testing; or a whole-exome, whole-transcriptome (WES\/WTS) comprehensive genomic profiling to inform use of targeted therapies. The budget impact and survival implications of WES\/WTS were compared head to head with the other testing approaches, and uncertainty was assessed in sensitivity analyses. In scenario analyses, tests that incorporate both DNA and RNA were compared with tests using DNA sequencing alone when assuming the prevalence of fusions that can only be identified by RNA ranged from 2.5% to 14%.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Compared with no testing, WES\/WTS reduced costs by $8,809 in US dollars (USD) per patient tested while increasing median overall survival by an average of 3.9 months. When compared with sequential single-gene testing, use of WES\/WTS decreased costs by $14,602 (USD) per patient and had a minimal survival benefit. A test that included both RNA and DNA sequencing reduced costs by $400-$1,724 (USD) and increased identification of actionable alterations by 2.3%-13.0% across the range of fusion prevalence.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Use of WES\/WTS improved clinical outcomes while reducing costs. These findings should be considered when choosing between tumor profiling approaches.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/po-24-00640","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T19:59:11Z","timestamp":1750190351000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":5,"title":["Costs and Benefits of Whole-Exome, Whole-Transcriptome Sequencing in Patients With Advanced Non\u2013Small Cell Lung Cancer"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6808-8267","authenticated-orcid":true,"given":"Jesse D.","family":"Ortendahl","sequence":"first","affiliation":[{"name":"Stratevi LLC, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6549-0069","authenticated-orcid":true,"given":"Gebra","family":"Cuyun Carter","sequence":"additional","affiliation":[{"name":"Exact Sciences Corporation, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snehal G.","family":"Thakkar","sequence":"additional","affiliation":[{"name":"Exact Sciences Corporation, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8357-8569","authenticated-orcid":true,"given":"Katalin","family":"Bognar","sequence":"additional","affiliation":[{"name":"Partnership for Health Analytic Research (PHAR), LLC, Beverly Hills, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7708-6656","authenticated-orcid":true,"given":"David W.","family":"Hall","sequence":"additional","affiliation":[{"name":"Exact Sciences Corporation, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4827-8613","authenticated-orcid":true,"given":"Yara","family":"Abdou","sequence":"additional","affiliation":[{"name":"University of North Carolina, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1784-048X","authenticated-orcid":false,"given":"David","family":"Gandara","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center, Davis, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_6_2_2","unstructured":"National Cancer Institute: Cancer of the lung and bronchus\u2014Cancer stat facts. SEER. https:\/\/seer.cancer.gov\/statfacts\/html\/lungb.html"},{"key":"e_1_3_6_3_2","unstructured":"National Cancer Institute: Drugs approved for lung cancer 2011. https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/lung"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13061117"},{"key":"e_1_3_6_5_2","article-title":"Disparities in biomarker testing and clinical trial enrollment among patients with lung, breast, or colorectal cancers in the United States","author":"Bruno DS","unstructured":"Bruno DS, Hess LM, Li X, et al: Disparities in biomarker testing and clinical trial enrollment among patients with lung, breast, or colorectal cancers in the United States. JCO Precis Oncol 10.1200\/PO.21.00427","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2023.03.002"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.014"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02767"},{"key":"e_1_3_6_9_2","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for non-small cell lung cancer version 4.2023. \u00a9 National Comprehensive Cancer Network Inc 2023. All rights reserved. To view the most recent and complete version of the guideline go online to NCCN.org"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.02.001"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100336"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e21114"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.08.022"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27945"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad005"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30020180"},{"key":"e_1_3_6_17_2","article-title":"Modeling costs and life-years gained by population-wide next-generation sequencing or single-gene testing in nonsquamous non-small-cell lung cancer in the United States","author":"Lemmon CA","unstructured":"Lemmon CA, Zhou J, Hobbs B, et al: Modeling costs and life-years gained by population-wide next-generation sequencing or single-gene testing in nonsquamous non-small-cell lung cancer in the United States. JCO Precis Oncol 10.1200\/PO.22.00294","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2019.11.006"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2019.18309"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.06.012"},{"key":"e_1_3_6_21_2","unstructured":"U.S. Bureau of Labor Statistics: CPI inflation calculator\u2014Consumer Price Index for all urban consumers (CPI-U). US Bur Labor Stat CPI Inflat Calc 2024. https:\/\/www.bls.gov\/data\/inflation_calculator.htm"},{"key":"e_1_3_6_22_2","unstructured":"National Cancer Institute: SEER*Explorer application. https:\/\/seer.cancer.gov\/statistics-network\/explorer"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2021.592997"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0341-y"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2018.1523849"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.04.003"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2020.10.005"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw337.24"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0127"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00206-y"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27877"},{"key":"e_1_3_6_32_2","unstructured":"Centers for Medicare and Medicaid Services: Clinical laboratory fee schedule 2022. https:\/\/www.cms.gov\/medicare\/medicare-fee-for-service-payment\/clinicallabfeesched"},{"key":"e_1_3_6_33_2","volume-title":"Physicians\u2019 Fee and Coding Guide","author":"InHealth Professional Services","year":"2021","unstructured":"InHealth Professional Services. Physicians\u2019 Fee and Coding Guide. Atlanta, GA: InHealth Professional Services; 2021."},{"key":"e_1_3_6_34_2","unstructured":"Wolters Kluwer Price Rx 2024. https:\/\/pricerx.medispan.com\/"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0018"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv382"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e17520"},{"key":"e_1_3_6_38_2","unstructured":"United States Bureau: Annual social and economic supplements. Census.gov. https:\/\/www.census.gov\/data\/datasets\/time-series\/demo\/cps\/cps-asec.html"},{"key":"e_1_3_6_39_2","unstructured":"Exact Sciences: Market research data [data on file] 2023"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.18_suppl.lba7500"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71173-8"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03136"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100332"},{"key":"e_1_3_6_45_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002787"},{"key":"e_1_3_6_46_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005653"},{"key":"e_1_3_6_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7"},{"key":"e_1_3_6_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30691-6"},{"key":"e_1_3_6_49_2","unstructured":"Novartis Pharmaceuticals: Study of selective BRAF kinase inhibitor dabrafenib monotherapy twice daily and in combination with dabrafenib twice daily and trametinib once daily in combination therapy in subjects with BRAF V600E mutation positive metastatic (stage IV) non-small cell lung cancer. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01336634"},{"key":"e_1_3_6_50_2","unstructured":"Genentech Inc: Highlights of prescribing information Alecensa\u00ae (alectinib) 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208434s003lbl.pdf"},{"key":"e_1_3_6_51_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0225"},{"key":"e_1_3_6_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e29272"},{"key":"e_1_3_6_53_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.6371"},{"key":"e_1_3_6_54_2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10080521"},{"key":"e_1_3_6_55_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.23.00601"},{"key":"e_1_3_6_56_2","article-title":"Impact of clinical practice gaps on the implementation of personalized medicine in advanced non-small-cell lung cancer","author":"Sadik H","unstructured":"Sadik H, Pritchard D, Keeling DM, et al: Impact of clinical practice gaps on the implementation of personalized medicine in advanced non-small-cell lung cancer. JCO Precis Oncol 10.1200\/PO.22.00246","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_6_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.06.017"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-24-00640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T19:59:15Z","timestamp":1750190355000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-24-00640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1200\/PO-24-00640"],"URL":"https:\/\/doi.org\/10.1200\/po-24-00640","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"2024-09-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-31","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2400640"}}